Life Sciences

Agiliti Set to Go Private in $2.5B Deal By THL Partners

Agiliti is withdrawing from the public market, a move that comes less than three...

FDA Approves Allecra’s Exblifep for Urinary Tract Infec...

In recent developments, the FDA has greenlighted one antibiotic combination ther...

Following FDA rejection, AstraZeneca finally gives up U...

AstraZeneca and FibroGen have concluded their collaboration on the oral anemia m...

Rovi’s Expansion in Pharmaceutical Production with Moderna

The Laboratorios Farmacéuticos Rovi and Moderna partnership has recently achieve...

Prolonged Epigenetic Suppression in Mice Strengthens Ar...

Recent mouse study findings suggest that epigenetic gene silencing could effecti...

Study Shows Roche’s Xolair Diminishes Severe Food Aller...

Xolair, a medication jointly marketed by Roche and Novartis, has emerged as a so...

275 Million New Genetic Variants Discovered by Researchers

In a recent investigation, scientists scrutinized the genetic composition of 250...

Bristol Myers Squibb Expands Irish Campus with $400M In...

Bristol Myers Squibb (BMS) has disclosed a significant infusion of $400 million ...

Breakthrough Antibiotic Shows Promise Against Resistant...

Amidst the concerning rise of drug-resistant strains of gonorrhea, a recent brea...

Rapt Pharma Clinical Trial for Atopic Dermatitis Placed...

Rapt Therapeutics faces a daunting challenge as the U.S. Food and Drug Administr...

European Commission Approves Pfizer’s Velsipity for Ulc...

The European Commission has granted its approval to Pfizer’s Velsipity for the t...

AstraZeneca’s Tagrisso-Chemo Combination Bags FDA Approval

The Food and Drug Administration (FDA) has granted approval to AstraZeneca’s Tag...

First T-cell treatment for a solid tumor Amtagvi approv...

The emergence of T-cell therapy has revolutionized the treatment of certain bloo...

New Player Latigo in Pain Biotech Challenges Vertex

A new contender has emerged in the domain of pain-focused biotechnology, marking...

Denali-Sanofi’s ALS Candidate Falls Short in Mid-Stage ...

Denali and Sanofi have been working together since 2018, when they reached an ag...

Setbacks Mount for Gilead’s Magrolimab Trials as FDA En...

In a chain of unfolding events reminiscent of the tumbling of dominos, Gilead Sc...